Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Remdesivir

- PMLiVE

NICE recommends two AI-powered software tools for stroke diagnosis in NHS

Brainomix's e-Stroke and Ischemaview’s RapidAI were reported by the health technology assessment agency to improve access to treatment for stroke patients

- PMLiVE

Study finds vaccination against COVID-19 reduces long COVID symptoms

The results could help inform public health strategies and vaccination campaigns

- PMLiVE

Pfizer’s Talzenna recommended by NICE for advanced breast cancer

An estimated 300 patients will be eligible for treatment with the PARP inhibitor

- PMLiVE

Pfizer’s COVID-19 antiviral Paxlovid recommended by NICE for expanded use

The latest guidance will mean an estimated 5.3 million people will be eligible to access Paxlovid

- PMLiVE

Bristol Myers Squibb’s Opdualag recommended by NICE for advanced melanoma

More than 16,700 new cases of melanoma are diagnosed in the UK every year

- PMLiVE

AstraZeneca/Merck’s Lynparza recommended by NICE for advanced prostate cancer

The combination therapy has been recommended for patients regardless of biomarker status

- PMLiVE

Gilead gains rights to Compugen’s immunotherapy programme in deal worth $848m

The high affinity antibody blocks the interaction between IL-18 binding protein and IL-18

- PMLiVE

AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer

Approximately 7,400 new cases of the disease are diagnosed in the UK every year

- PMLiVE

Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO

Nuvaxovid XBB.1.5 is now approved for emergency use in all 194 WHO member states

- PMLiVE

AstraZeneca’s rare disease unit receives NICE recommendation for Wolman disease therapy in infants

The enzyme replacement therapy will become the first treatment available on the NHS for the rare genetic disease

- PMLiVE

New report identifies key issues with NICE’s methods for evaluating Alzheimer’s drugs

Several disease-modifying treatments for use in Alzheimer's disease are at varying stages of development and regulatory approval

- PMLiVE

NICE recommends Chiesi’s alpha-mannosidosis enzyme replacement therapy

Alpha-mannosidosis, an extremely rare inherited condition characterised by a broad range of impairments, affects approximately 25 people in England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links